人类遗传变异对基于CRISPR的治疗性基因组编辑的影响
该研究分析ExAC与1000 Genomes数据,评估人类遗传变异如何影响治疗性基因组编辑中Cas核酸酶靶点选择,发现遗传变异对某些Cas核酸酶靶位点的干扰更大,并提供在高 efficacy 多样人群中预测高效的guide RNA汇编;聚焦12个治疗相关基因分析脱靶候选位点,提示在大群体中多数候选脱靶位点罕见,强调通过全基因组测序预筛患者以确保安全。
要点
- 人类遗传变异对某些Cas核酸酶靶位点的干扰大于其他核酸酶。
- 提供预测在多样患者人群中高效的guide RNA汇编。
- 大群体中多数候选脱靶位点罕见,强调全基因组测序预筛患者以确保安全。
核心结论
- 人类遗传变异影响治疗性基因组编辑的靶点选择,且对某些Cas核酸酶靶位点的干扰更大。
- 在大群体中多数候选脱靶位点罕见,强调通过全基因组测序预筛患者以确保安全。
- 信息可与guide RNA选择的经验方法整合,形成设计CRISPR治疗以最大化跨患者群体疗效与安全的框架。
研究设计与样本
- 分析近期发布的ExAC与1000 Genomes数据集,以确定人类遗传变异在治疗性基因组编辑背景下如何影响Cas核酸内切酶的靶点选择。
- 进一步分析聚焦12个治疗相关基因,考虑遗传变异如何影响这些位点的脱靶候选。
主要发现
- 遗传变异对某些Cas核酸内切酶靶位点的干扰大于其他核酸酶。
- 提供预测在多样患者人群中高效的guide RNA汇编。
- 在大群体中多数候选脱靶位点罕见。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CRISPR-Cas genome-editing methods hold immense potential as therapeutic tools to fix disease-causing mutations at the level of DNA. In contrast to typical drug development strategies aimed at targets that are highly conserved among individual patients, treatment at the genomic level must contend with substantial inter-individual natural genetic variation. Here we analyze the recently released ExAC and 1000 Genomes data sets to determine how human genetic variation impacts target choice for Cas endonucleases in the context of therapeutic genome editing. We find that this genetic variation confounds the target sites of certain Cas endonucleases more than others, and we provide a compendium of guide RNAs predicted to have high efficacy in diverse patient populations. For further analysis, we focus on 12 therapeutically relevant genes and consider how genetic variation affects off-target candidates for these loci. Our analysis suggests that, in large populations of individuals, most candidate off-target sites will be rare, underscoring the need for prescreening of patients through whole-genome sequencing to ensure safety. This information can be integrated with empirical methods for guide RNA selection into a framework for designing CRISPR-based therapeutics that maximizes efficacy and safety across patient populations.
引用
- Scott DA, Zhang F. Implications of human genetic variation in CRISPR-based therapeutic genome editing. Nat Med. 2017. PMID: 28759051. doi:10.1038/nm.4377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。